Analytical considerations for mass spectrometry profiling in serum biomarker discovery.
The potential of using mass spectrometry profiling as a diagnostic tool has been demonstrated for a wide variety of diseases. Various cancers and cancer-related diseases have been the focus of much of this work because of both the paucity of good diagnostic markers and the knowledge that early diagnosis is the most powerful weapon in treating cancer. The implementation of mass spectrometry as a routine diagnostic tool has proved to be difficult, however, primarily because of the stringent controls that are required for the method to be reproducible. The method is evolving as a powerful guide to the discovery of biomarkers that could, in turn, be used either individually or in an array or panel of tests for early disease detection. Using proteomic patterns to guide biomarker discovery and the possibility of deployment in the clinical laboratory environment on current instrumentation or in a hybrid technology has the possibility of being the early diagnosis tool that is needed.
Whiteley
Gordon R
GR
Clinical Proteomics Reference Lab, Advanced Technology Program, SAIC-Frederick, NCI-Frederick, PO Box B, Frederick, MD 21702, USA. WhiteleyG@ncifcrf.gov
Colantonio
Simona
S
Sacconi
Andrea
A
Saul
Richard G
RG
D015415:Biomarkers / Q000097:blood*; D006801:Humans; D007120:Immunochemistry; D040901:Proteomics / Q000379:methods*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D015415:Biomarkers